These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29324805)

  • 1. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
    Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
    PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
    Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
    J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
    Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
    Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
    Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
    Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
    Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
    Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
    Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
    Kim MC; Lee YN; Ko EJ; Lee JS; Kwon YM; Hwang HS; Song JM; Song BM; Lee YJ; Choi JG; Kang HM; Quan FS; Compans RW; Kang SM
    Mol Ther; 2014 Jul; 22(7):1364-1374. PubMed ID: 24590045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
    Music N; Reber AJ; Kim MC; York IA; Kang SM
    Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
    Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
    J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs.
    Kang HJ; Chu KB; Lee DH; Lee SH; Park BR; Kim MC; Kang SM; Quan FS
    PLoS One; 2019; 14(6):e0216871. PubMed ID: 31246961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.
    Quan FS; Kim MC; Lee BJ; Song JM; Compans RW; Kang SM
    Virology; 2012 Sep; 430(2):127-35. PubMed ID: 22658901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.
    Kim YJ; Lee YT; Kim MC; Lee YN; Kim KH; Ko EJ; Song JM; Kang SM
    Front Immunol; 2017; 8():1730. PubMed ID: 29276514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.